Semaglutide effects: the benefits, the side effects, and who should be careful.

Start here

This page covers what semaglutide actually does to people — both the upsides and the downsides — in plain language. Two kinds of information sit here, kept carefully apart. The first is what people in patient communities report: their own experiences, which are real but unverified and not the same as proof. The second is what the published safety literature and the approved label say, each backed by a numbered source.

In short: most people report that hunger and cravings drop sharply and weight comes off, and people with diabetes report better blood-sugar numbers. The most common complaint by far is stomach upset — nausea, odd burps, changed bowel habits — usually worst early on and after each dose increase. There are also specific cautions worth knowing, from a thyroid-related boxed warning to advice against use in pregnancy. None of this is medical advice, and no doses are recommended anywhere on this page.

What people report

These are effects described by the patient and research-use community — anecdotal, not clinical evidence, and not verified by controlled trials. They are grouped below as benefits first, then adverse effects. No doses are attached to any of them.

Reported benefits

• A quieter relationship with food (frequently reported). The single most common thing people describe is that the constant mental chatter about food goes quiet, often within the first week or two. Many say they feel full faster, eat a third to a half of their old portions, and stop circling back to the next meal. People often call this the most life-changing part.
• Fewer cravings (frequently reported). Sugar and sweet cravings reportedly drop sharply or disappear, and fried, greasy or high-fat foods stop appealing — sometimes turning slightly off-putting. Several people say they drift naturally toward fruit, vegetables and lighter meals.
• Weight loss (frequently reported). The large majority of reviewers report losing weight, often steady and substantial over several months, with the pace slowing after the early stretch. Many tie it directly to simply eating much less.
• Better blood-sugar control (commonly reported). Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with some describing morning and long-term numbers dropping into normal ranges.
• Less interest in alcohol (occasionally reported). A recurring side observation is that the urge to drink fades along with food cravings; some people say they simply lose interest in drinking.

Reported adverse effects

• Nausea, sometimes with vomiting (frequently reported). Nausea is the most reported side effect — described by roughly a third of reviewers — and a subset escalates to vomiting at its worst. It tends to peak in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. Many manage it with smaller, lighter meals and plenty of water.
• Sulfur or "egg" burps (commonly reported). A distinctive complaint is foul-smelling burps compared to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long. People note these show up far more often than official lists suggest.
• Bowel changes — constipation and diarrhea (commonly reported). People report both extremes, sometimes alternating. Constipation can mean hard, infrequent stools; diarrhea is often worse in the days right after a dose or after rich food.
• Acid reflux and heartburn (occasionally reported). Reflux, heartburn and indigestion come up often, sometimes alongside the burping and bloating, and tend to track with dose increases.
• Tiredness early on (commonly reported). Low energy comes up often, especially in the first day or two after an injection and during the early weeks, usually easing with time.
• Food aversions, taste changes and over-suppressed appetite (occasionally reported). Beyond eating less, some report active aversions to fatty or meaty foods, a metallic taste, and a heightened, unpleasant sensitivity to smells likened to morning sickness. For a few, appetite drops so far they must remind themselves to eat.
• Hair shedding and a gaunter face (sometimes reported). A smaller group reports more hair shedding a few months in, plus a thinner, more hollow face. Both are widely attributed to losing weight quickly rather than to the drug, and the shedding is generally described as temporary.
• Headaches and dizziness (occasionally reported). Often in the first days of a new dose and frequently linked to not drinking or eating enough; many say staying hydrated helps.
• Injection-site reactions (sometimes reported). Mild redness, itching, a small bump or tenderness where people inject, generally described as minor and short-lived.

Semaglutide side effects: safety & cautions

The cautions below come from clinical trials, the approved label, and pharmacovigilance (post-marketing safety monitoring), each cited. Where a concern is theoretical or extrapolated, it is labeled as such.

Stomach and gut intolerance, especially during dose increases. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in trials and the leading reason people stop. In a pooled analysis of the weight-management program they were mostly mild-to-moderate and transient, clustered around the titration period, and a dedicated safety review reported nausea in roughly one-third of patients ^[5][16]. This is mechanism, not bad luck: the slowed stomach emptying that drives the gut effects is part of how the drug works ^[9].

Personal or family history of medullary thyroid cancer or MEN-2 (boxed warning). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, based on rodent studies where such tumors appeared at very high exposures. A dedicated review concluded that human data do not establish a clear increase in thyroid cancer from semaglutide, so the signal is best described as unconfirmed in humans — but a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a reason not to use it ^[17][5].

Acute pancreatitis (class warning). Inflammation of the pancreas is a recognized class warning, and treatment is conventionally stopped if it is suspected. A semaglutide safety review notes that pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn, owing to low numbers rather than confirmed associations — so this is precautionary, not a demonstrated risk increase ^[5].

Gallbladder and biliary disease. A dedicated safety review found an increased risk of gallstones with semaglutide. It is attributed largely to the rate and amount of weight loss rather than direct drug toxicity, but the increase versus placebo is a real trial and pharmacovigilance finding, not merely theoretical ^[5].

Pre-existing diabetic eye disease with rapid blood-sugar correction. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent with semaglutide (hazard ratio 1.76), concentrated in people who already had retinopathy and whose blood sugar dropped quickly ^[2]. The leading explanation is early worsening driven by the speed of correction rather than direct harm to the retina; monitoring is advised when glucose is brought down fast ^[5].

Loss of muscle along with fat. A body-composition substudy found the weight lost with semaglutide includes both fat and a meaningful share of lean (muscle) mass ^[18]. Because rapid, large weight loss can erode muscle, this raises a sarcopenia concern, especially in older adults, and has driven interest in protein intake and resistance training. The lean-mass loss is observed; the downstream muscle-weakness risk is a reasoned extrapolation.

Weight regain after stopping. Stopping is followed by substantial regain. In the STEP 1 extension, people regained a mean of about 11.6 percentage points of body weight within a year of stopping, and cardiometabolic gains drifted back toward baseline; the STEP 4 withdrawal trial showed the same pattern after switching to placebo ^[19][20]. This frames the drug as a long-term, not a one-time, intervention.

Hair shedding with rapid weight loss. A pharmacovigilance analysis flagged a reporting signal for hair loss with semaglutide and tirzepatide, and a separate study linked diffuse shedding (telogen effluvium) to the magnitude and speed of weight loss ^[21][22]. The signal is most consistent with rapid-weight-loss-associated shedding — usually reversible — rather than direct drug toxicity.

Pregnancy: not advised, with a long washout. Semaglutide is contraindicated in pregnancy on the label. Because it clears slowly — a half-life of about a week, with effectively full clearance only around five weeks after the last dose — guidance advises stopping well ahead of a planned pregnancy (commonly cited as roughly two months) ^[23].

The oral tablet must be taken fasted. Oral semaglutide is paired with an absorption enhancer (SNAC) and has very low oral availability (about 0.4-1%), so it must be taken on an empty stomach with only a little water, apart from other food, drink and medicines. Administration errors can sharply cut how much is absorbed ^[24][23]. This is a formulation requirement, not a toxicity.

Narrow-margin oral drugs during dose changes. A systematic review found the delayed stomach emptying from GLP-1 receptor agonists generally does not cause clinically important drug interactions, but advised caution and monitoring for narrow-therapeutic-index oral medicines, especially during dose increases ^[25]. Overall interaction risk is characterized as low.

Then and now

Semaglutide is recent, but its story already has chapters. It came out of decades of incretin-peptide chemistry, built on an earlier GLP-1 medicine and re-engineered for once-weekly dosing through DPP-4 resistance and albumin binding. It first reached FDA approval for type 2 diabetes in 2017, gained an oral once-daily form around 2019-2020, and a chronic weight-management use in 2021 ^[23]. Its cardiovascular evidence (SELECT) read out in 2023 and its kidney evidence (FLOW) in 2024, with the matching heart and kidney indications following, and a fatty-liver (MASH) indication added in 2025 ^[3][6].

There is also a supply chapter. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to make semaglutide; once the shortage was declared resolved in early 2025, that pathway was curtailed ^[2]. The compounded-supply question is covered on the dosage page.